Arvinas Inc (ARVN) - Total Assets
Based on the latest financial reports, Arvinas Inc (ARVN) holds total assets worth $675.10 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Arvinas Inc - Total Assets Trend (2016–2025)
This chart illustrates how Arvinas Inc's total assets have evolved over time, based on quarterly financial data. Also see ARVN company net worth for the company's overall valuation and market capitalisation.
Arvinas Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Arvinas Inc's total assets of $675.10 Million consist of 97.6% current assets and 2.4% non-current assets. Review ARVN current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.9% |
| Accounts Receivable | $6.40 Million | 0.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Arvinas Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Arvinas Inc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arvinas Inc's current assets represent 97.6% of total assets in 2025, a decrease from 98.3% in 2016.
- Cash Position: Cash and equivalents constituted 19.9% of total assets in 2025, up from 13.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 0.9% of total assets.
Arvinas Inc Competitors by Total Assets
Key competitors of Arvinas Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Arvinas Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.91 | 5.64 | 8.64 |
| Quick Ratio | 7.91 | 5.64 | 8.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $569.70 Million | $731.70 Million | $1.39 Billion |
Arvinas Inc - Advanced Valuation Insights
This section examines the relationship between Arvinas Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.06 |
| Latest Market Cap to Assets Ratio | 0.75 |
| Asset Growth Rate (YoY) | -34.2% |
| Total Assets | $717.90 Million |
| Market Capitalization | $540.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Arvinas Inc's assets below their book value (0.75x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Arvinas Inc's assets decreased by 34.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Arvinas Inc (2016–2025)
The table below shows the annual total assets of Arvinas Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $717.90 Million | -34.22% |
| 2024-12-31 | $1.09 Billion | -16.34% |
| 2023-12-31 | $1.30 Billion | +2.82% |
| 2022-12-31 | $1.27 Billion | -19.78% |
| 2021-12-31 | $1.58 Billion | +120.46% |
| 2020-12-31 | $717.40 Million | +137.83% |
| 2019-12-31 | $301.64 Million | +51.36% |
| 2018-12-31 | $199.28 Million | +198.11% |
| 2017-12-31 | $66.85 Million | +76.21% |
| 2016-12-31 | $37.94 Million | -- |
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing… Read more